NCT06838338View on ClinicalTrials.gov

JAB-21822 Combined With Chemotherapy in Second-line KRAS G12C CRC

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 29, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Colorectal Cancer
Interventions
DRUG

JAB-21822

Tablet, oral, 800 mg/QD, until PD or intolerable toxicity

DRUG

standard second-line chemotherapy

The second line standard chemotherapy regimen recommended by clinical practice

DRUG

Bevacizumab

According to the assessment by investigator

Trial Locations (1)

100101

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Jian Li

OTHER